Trastuzumab Deruxtecan in HER2-Low Advanced Breast Cancer | NEJM

Sdílet
Vložit
  • čas přidán 6. 07. 2022
  • Patients with HER2-low breast cancer have limited targeted treatment options for progressing disease after primary therapy. An antibody-drug conjugate has shown efficacy in early trials.
    New research findings are summarized in a short video.
    To see the full article, follow this link: nej.md/3aCIH6d
  • Věda a technologie

Komentáře • 2

  • @user-lb2yv9yr4r
    @user-lb2yv9yr4r Před rokem +1

    Как перевести на русский язык?